Biotech Values

[io_io]

re:DNDN


ChemDiv Extends and Expands Collaboration With Dendreon for the Development of New Cancer Therapies
Friday April 1, 9:00 am ET


SAN DIEGO, April 1 /PRNewswire/ -- ChemDiv, Inc. (Chemical Diversity), a leading integrated provider of discovery services, based in San Diego, California, announced today that it has extended and expanded its existing collaboration with Dendreon Corporation (Nasdaq: DNDN - News). Chemical Diversity supplies Dendreon with medicinal and custom chemistry services to support Dendreon's discovery programs for targeted cancer therapies. Financial details of the collaboration were not disclosed.
ADVERTISEMENT


Dr. Alex Kiselyov, Vice President of Global Chemistry for ChemDiv, Inc. stated, "We are very pleased that Dendreon has repeatedly chosen ChemDiv, Inc. for our expertise in lead optimization and custom chemistry to complement their internal capabilities. We look forward to supporting Dendreon in its small molecule program through our de novo synthesis of custom libraries and medicinal chemistry efforts."

"Dendreon's goal is to develop new cancer treatments using a variety of technological approaches, and we work with technology leaders to reach that goal," said Dr. Ofir Moreno, Senior Director of Chemistry at Dendreon Corporation. "We selected ChemDiv Inc. for its ability to consistently execute complex chemistry and deliver quality results. Chemical Diversity has earned an excellent reputation, and we look forward to their continued involvement in our small molecule discovery programs."